TY - JOUR
T1 - Blood pressure and outcomes in very old hypertensive coronary artery disease patients
T2 - An INVEST substudy
AU - Denardo, Scott J.
AU - Gong, Yan
AU - Nichols, Wilmer W.
AU - Messerli, Franz H.
AU - Bavry, Anthony A.
AU - Cooper-Dehoff, Rhonda M.
AU - Handberg, Eileen M.
AU - Champion, Annette
AU - Pepine, Carl J.
PY - 2010/8
Y1 - 2010/8
N2 - Background: Our understanding of the growing population of very old patients (aged <80 years) with coronary artery disease and hypertension is limited, particularly the relationship between blood pressure and adverse outcomes. Methods: This was a secondary analysis of the INternational VErapamil SR-Trandolapril STudy (INVEST), which involved 22,576 clinically stable hypertensive coronary artery disease patients aged <50 years. The patients were grouped by age in 10-year increments (aged <80, n = 2180; 70<80, n = 6126; 60<70, n = 7602; <60, n = 6668). Patients were randomized to either verapamil SR- or atenolol-based treatment strategies, and primary outcome was first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke. Results: At baseline, increasing age was associated with higher systolic blood pressure, lower diastolic blood pressure, and wider pulse pressure (P <.001). Treatment decreased systolic, diastolic, and pulse pressure for each age group. However, the very old retained the widest pulse pressure and the highest proportion (23.6%) with primary outcome. The adjusted hazard ratio for primary outcomes showed a J-shaped relationship among each age group with on-treatment systolic and diastolic pressures. The systolic pressure at the hazard ratio nadir increased with increasing age, highest for the very old (140 mm Hg). However, diastolic pressure at the hazard ratio nadir was only somewhat lower for the very old (70 mm Hg). Results were independent of treatment strategy. Conclusion: Optimal management of hypertension in very old coronary artery disease patients may involve targeting specific systolic and diastolic blood pressures that are higher and somewhat lower, respectively, compared with other age groups.
AB - Background: Our understanding of the growing population of very old patients (aged <80 years) with coronary artery disease and hypertension is limited, particularly the relationship between blood pressure and adverse outcomes. Methods: This was a secondary analysis of the INternational VErapamil SR-Trandolapril STudy (INVEST), which involved 22,576 clinically stable hypertensive coronary artery disease patients aged <50 years. The patients were grouped by age in 10-year increments (aged <80, n = 2180; 70<80, n = 6126; 60<70, n = 7602; <60, n = 6668). Patients were randomized to either verapamil SR- or atenolol-based treatment strategies, and primary outcome was first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke. Results: At baseline, increasing age was associated with higher systolic blood pressure, lower diastolic blood pressure, and wider pulse pressure (P <.001). Treatment decreased systolic, diastolic, and pulse pressure for each age group. However, the very old retained the widest pulse pressure and the highest proportion (23.6%) with primary outcome. The adjusted hazard ratio for primary outcomes showed a J-shaped relationship among each age group with on-treatment systolic and diastolic pressures. The systolic pressure at the hazard ratio nadir increased with increasing age, highest for the very old (140 mm Hg). However, diastolic pressure at the hazard ratio nadir was only somewhat lower for the very old (70 mm Hg). Results were independent of treatment strategy. Conclusion: Optimal management of hypertension in very old coronary artery disease patients may involve targeting specific systolic and diastolic blood pressures that are higher and somewhat lower, respectively, compared with other age groups.
KW - Age
KW - Blood pressure control
KW - Coronary artery disease
KW - Elderly
KW - Epidemiology
KW - Hypertension
UR - http://www.scopus.com/inward/record.url?scp=77955476577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955476577&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2010.02.014
DO - 10.1016/j.amjmed.2010.02.014
M3 - Article
C2 - 20670726
AN - SCOPUS:77955476577
SN - 0002-9343
VL - 123
SP - 719
EP - 726
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 8
ER -